Utility of Elective Neck Dissection in Clinically Node‐Negative Parotid Malignancy
Otolaryngology–Head and Neck Surgery · 2023-10 · 169 (4) · 917-927
DOI: 10.1002/ohn.264 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, published online on 2023-02-17. Written by Sudeepti Vedula and 4 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Major MEDLINE topics: Parotid Neoplasms, Carcinoma, Squamous Cell. Cited 8 times so far (Crossref); 23 references.
Abstract (original language)
Objective
We sought to investigate the utility of elective neck dissection (END) in clinically node‐negative parotid malignancy through the evaluation of factors that are associated with receiving END and survival analysis of patients who received END. Study Design Retrospective cohort database study.
Setting
The National Cancer Database (NCDB).
Methods
The NCDB was used to extract patients with clinically node‐negative parotid malignancy. END was defined as having 5 or more lymph nodes examined pathologically, as previously defined in the literature. Univariate and multivariate analyses were used to compare predictors of receiving END, rates of occult metastasis, and survival.
Results
Of the 9405 included patients, 3396 (36.1%) underwent an END. END was most frequently performed for squamous cell carcinoma (SCC) and salivary duct histology. All other histologies were significantly less likely to undergo END compared to SCC ( p < .05). Salivary ductal carcinoma and adenocarcinoma had the greatest rates of occult node disease (39.8% and 30.0%, respectively), followed by SCC (29.8%). Kaplan‐Meier survival analysis showed a statistically significant increase in 5‐year overall survival in patients who received END with poorly differentiated mucoepidermoid (56.2% vs 48.5%, p = .004) along with moderately and poorly differentiated SCC (43.2% vs 34.9%, p = .002; 48.9% vs 36.2%, p < .001, respectively).
Conclusion
Histological classification is a benchmark for determining which patients should receive an END. We demonstrated an increase in overall survival in patients who undergo END with poorly differentiated tumors of mucoepidermoid and SCC histology. As such, histology should be considered along with clinical T‐stage and rate of occult nodal metastasis to determine eligibility for END.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Department of Neurological Surgery, Center for Skull Base and Pituitary Surgery, Rutgers New Jersey Medical School, Neurological Institute of New Jersey, Newark, New Jersey, USA.
ORCID profiles: Gregory L Barinsky
Cite
APA
Vedula, S., Shah, Y. S., Barinsky, G. L., Baredes, S., & Park, R. C. W. (2023). Utility of Elective Neck Dissection in Clinically Node‐Negative Parotid Malignancy. Otolaryngology–Head and Neck Surgery, 169(4), 917-927. https://doi.org/10.1002/ohn.264
Vancouver
Vedula S, Shah YS, Barinsky GL, Baredes S, Park RCW. Utility of Elective Neck Dissection in Clinically Node‐Negative Parotid Malignancy. Otolaryngology–Head and Neck Surgery. 2023;169(4):917-927. doi:10.1002/ohn.264
BibTeX
@article{Vedula2023,
author = {Vedula, Sudeepti and Shah, Yash S and Barinsky, Gregory L and Baredes, Soly and Park, Richard C W},
title = {Utility of Elective Neck Dissection in Clinically Node‐Negative Parotid Malignancy},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
volume = {169},
number = {4},
pages = {917--927},
doi = {10.1002/ohn.264}
}
EUVIMED